SCHEMBL4872065

SCHEMBL4872065

O=C(CNS(=O)(=O)c1ccc2c(c1)OCCO2)Nc1ccc(Cl)cc1C(O)c1ccccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.53
ALDH1A1 P00352 8/20 0.48
MAPT P10636 5/20 0.48
LMNA P02545 2/20 0.48
RECQL P46063 1/20 0.48
KMT2A Q03164 2/20 0.46
HTT P42858 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
GCKR Q14397 3/20 0.44
HPGD P15428 4/20 0.44
CYP2C9 P11712 1/20 0.44
PKM P14618 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253240 0.86 ALDH1A1 (0.46) MEP1BALDH1A1MAPTLMNAKMT2A
SCHEMBL3244695 0.85 CYP1A2 (0.48) ALDH1A1MAPTLMNAKMT2AHTT
SCHEMBL3247544 0.85 ALDH1A1 (0.48) MEP1BALDH1A1MAPTLMNAKMT2A
SCHEMBL3250956 0.84 CTSS (0.47) ALDH1A1MAPTLMNAKMT2AHTT
SCHEMBL3249174 0.84 L3MBTL1 (0.44) ALDH1A1MAPTLMNAKMT2AGAA
SCHEMBL3249144 0.82 MEP1B (0.54) MEP1BALDH1A1MAPTLMNARECQL
SCHEMBL3246435 0.82 ALDH1A1 (0.42) ALDH1A1MAPTLMNAKMT2AHTT
SCHEMBL3251363 0.81 SMN1; SMN2 (0.43) ALDH1A1MAPTLMNARECQLKMT2A
SCHEMBL3251156 0.81 FLT1 (0.42) ALDH1A1MAPTLMNAKMT2AHTT
SCHEMBL4869106 0.81 TSHR (0.47) MEP1BALDH1A1MAPTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 MEP1B 1627/4885ALDH1A1 2179/4885MAPT 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.